Recombinant Human TGF-β sRII - 50 µg

Transforming growth factor beta type II (TGFbeta RII) is a disulfide-linked homodimer and is a key inhibitor of epithelial cell growth and tumor suppressor gene.1 It also regulate cell differentiation and has critical regulatory roles in the process of tissue repair and remodeling.2 TGF beta RII plays an important role as a tumor suppressor in non-small cell lung cancer (NSCLC) carcinogenesis.1 TGF can be found in many different tissue types, including brain, heart, kidney, liver and testes. Over-expression of TGF can induce renal fibrosis, causing kidney disease, as well as diabetes, and ultimately end-stage renal disease (ESRD). Recent developments have found that, using certain types of protein antagonists against TGFβ receptors, can halt and in some cases reverse the effects of renal fibrosis. Three TGF-β receptor types can be distinguished by their structural and functional properties. Receptor types I and II have similar ligand binding affinities and can only be distinguished from each other by peptide mapping, both receptor types I and II have a high affinity for TGF-β1 and low affinity for TGF-β2. TGF-β receptor type III has a high affinity for both TGF-β1 and -β2.